Some 83 percent think Medicare should negotiate prescription drug prices for the Part D program. "The public thinks Medicare should negotiate drug prices just like the agency does for all other medical goods and services," says TSCL's Medicare and Social Security policy analyst, Mary Johnson. A complete repeal of the Affordable Care Act, known as
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February 14, 2017, the plaintiff voluntarily dismissed the putative securities class action lawsuit he had recently filed against the company and certain members of its...
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. In 2017, AmpliPhi plans to initiate phage therapy studies in severa
Analyst Ratings For ANI Pharmaceuticals (NASDAQ:ANIP) Today, ANI Pharmaceuticals (NASDAQ:ANIP) stock was downgraded by Roth Capital from Buy to Neutral with a price target of $69.00. There are 2 hold ratings, 3 buy ratings, 1 strong buy rating on the stock. The current consensus rating on ANI Pharmaceuticals (NASDAQ:ANIP) is Buy (Score: 2.83) with
DEAR DOCTOR: I had my thyroid removed because of papillary cancer, and my surgeon has advised me to take high levels of vitamin D. He says there may be a correlation between low vitamin D levels and the development of cancer and Alzheimer's disease. If I remember correctly, the normal blood range for vitamin D is between 30 and 60 nanograms per mil
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
CTI BioPharma Corp. today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Thursday, March 2 1:30 p.m. PT/ 4:30 p.m. ET/ 10:30 p.m. CET 1-877-719-9788 +1 719-325-4802. CTI BioPharma Corp. is a biopharmaceutical company focus
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
Earth Science Tech, Inc., an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidia
-Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today the hiring of John Wyatt as Vice President of Sales. We are thrilled to welcome John to the Cohera team, said Patrick Daly, President and CEO of Cohera Medical, Inc. Johns experience in the aesthetic medical device and biopharmace
Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the first patient has been dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007, the Company s gene therapy candidate for the treatment of Recessive Dystro
Earth Science Tech, Inc., Cannabis Sativa Inc., OWC Pharmaceutical Research Corporation, Canopy Growth Corporation, Mentor Capital Inc.. Just this morning Earth Science Tech, Inc. announced that it, "has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceuti
Flexion Therapeutics, Inc. today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate Zilretta in patients with osteoarthritis of the knee. The open-label study is expected to enroll approximately 200 patients at up to 20 clinical sites in the United S
REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 23, 2017/ PRNewswire/ Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will participate in a panel discussion entit
Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson& Johnson Innovation JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT.
-Research and Markets has announced the addition of the "Global Antibody Drug Conjugates Market By Drug, Pipeline Analysis Outlook 2022" report to their offering. The ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla.
A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission on October 14, 2016 and declared effective by the SEC on October 28, 2016. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed